全文获取类型
收费全文 | 41069篇 |
免费 | 5443篇 |
国内免费 | 194篇 |
专业分类
耳鼻咽喉 | 894篇 |
儿科学 | 1025篇 |
妇产科学 | 974篇 |
基础医学 | 4337篇 |
口腔科学 | 931篇 |
临床医学 | 6843篇 |
内科学 | 7977篇 |
皮肤病学 | 839篇 |
神经病学 | 3273篇 |
特种医学 | 1489篇 |
外国民族医学 | 2篇 |
外科学 | 6495篇 |
综合类 | 836篇 |
现状与发展 | 2篇 |
一般理论 | 24篇 |
预防医学 | 4615篇 |
眼科学 | 734篇 |
药学 | 2344篇 |
4篇 | |
中国医学 | 171篇 |
肿瘤学 | 2897篇 |
出版年
2023年 | 600篇 |
2022年 | 448篇 |
2021年 | 1080篇 |
2020年 | 965篇 |
2019年 | 927篇 |
2018年 | 1442篇 |
2017年 | 1209篇 |
2016年 | 1256篇 |
2015年 | 1442篇 |
2014年 | 1757篇 |
2013年 | 2405篇 |
2012年 | 2384篇 |
2011年 | 2359篇 |
2010年 | 1632篇 |
2009年 | 1539篇 |
2008年 | 1819篇 |
2007年 | 1764篇 |
2006年 | 1773篇 |
2005年 | 1562篇 |
2004年 | 1559篇 |
2003年 | 1412篇 |
2002年 | 1159篇 |
2001年 | 975篇 |
2000年 | 822篇 |
1999年 | 849篇 |
1998年 | 577篇 |
1997年 | 526篇 |
1996年 | 538篇 |
1995年 | 467篇 |
1994年 | 374篇 |
1993年 | 324篇 |
1992年 | 618篇 |
1991年 | 608篇 |
1990年 | 527篇 |
1989年 | 600篇 |
1988年 | 552篇 |
1987年 | 524篇 |
1986年 | 500篇 |
1985年 | 526篇 |
1984年 | 366篇 |
1983年 | 335篇 |
1982年 | 231篇 |
1981年 | 221篇 |
1979年 | 272篇 |
1978年 | 211篇 |
1977年 | 179篇 |
1976年 | 200篇 |
1974年 | 195篇 |
1973年 | 205篇 |
1972年 | 168篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
2.
3.
Kara S. Tanaka MD Veronica R. Andaya BA Steven W. Thorpe MD Kenneth R. Gundle MD James B. Hayden MD Yee-Cheen Duong MD Raffi S. Avedian MD David G. Mohler MD Lee J. Morse MD Melissa N. Zimel MD Richard J. O'Donnell MD Andrew Fang MD Robert Lor Randall MD Tina H. Tran BS Christin New BA Rosanna L. Wustrack MD other members of Study Group FORCE 《Journal of surgical oncology》2023,127(1):148-158
4.
5.
6.
7.
目的 探讨在苯妥英钠(Phenytoin,PHT)促进大鼠牙周膜干细胞(Rat periodontal ligament stem cells,rPDLSCs)、大鼠骨髓间充质干细胞(Rat Bone Marrow Mesenchymal Stem Cells,rBMMSCs)黏附于牙骨质过程中,整合素α5β1(Integrin α5β1)起到的作用。方法 提取大鼠BMMSCs和PDLSCs,培养并纯化。通过细胞鉴定后,将获得的两种细胞各分为4组:40 mg/L PHT处理组、40 mg/L PHT+整合素α5抗体处理组、40 mg/L PHT+整合素β1抗体处理组、PBS处理组,每组细胞放入置有牙骨质片的96孔板处理4 h后,检测黏附于牙骨质片上的细胞量并做以比较。最后,利用qRT-PCR和Western blot检测40 mg/L PHT组与对照组细胞的整合素α5、β1亚基的mRNA与蛋白表达量。结果 40 mg/L PHT可促进rBMMSCs及rPDLSCs黏附于牙骨质片,加入整合素α5、β1抗体后,均明显抑制了40 mg/L PHT对rBMMSCs、rPDLSCs黏附于牙骨质的促进作用(P<0.01)。qRT-PCR、Western-blot结果显示PHT处理组的整合素α5、β1亚基表达量高于空白对照组(P<0.05)。结论 40 mg/L PHT能促进rBMMSCs、rPDLSCs黏附于牙骨质,该作用与整合素α5β1的表达上调密切相关。 相似文献
8.
Archie L. Overmann DesRaj M. Clark Panagiotis Tsagkozis Rikard Wedin Jonathan A. Forsberg 《Journal of orthopaedic research》2020,38(10):2149-2156
Treatment decisions in patients with metastatic bone disease rely on accurate survival estimation. We developed the original PATHFx models using expensive, proprietary software and now seek to provide a more cost-effective solution. Using open-source machine learning software to create PATHFx version 2.0, we asked whether PATHFx 2.0 could be created using open-source methods and externally validated in two unique patient populations. The training set of a well-characterized, database records of 189 patients and the bnlearn package within R Version 3.5.1 (R Foundation for Statistical Computing), was used to establish a series of Bayesian belief network models designed to predict survival at 1, 3, 6, 12, 18, and 24 months. Each was externally validated in both a Scandinavian (n = 815 patients) and a Japanese (n = 261 patients) data set. Brier scores and receiver operating characteristic curves to assessed discriminatory ability. Decision curve analysis (DCA) evaluated whether models should be used clinically. DCA showed that the model should be used clinically at all time points in the Scandinavian data set. For the 1-month time point, DCA of the Japanese data set suggested to expect better outcomes assuming all patients will survive greater than 1 month. Brier scores for each curve demonstrate that the models are accurate at each time point. Statement of Clinical Significance: we successfully transitioned to PATHFx 2.0 using open-source software and externally validated it in two unique patient populations, which can be used as a cost-effective option to guide surgical decisions in patients with metastatic bone disease. 相似文献
9.
10.
Altan Ahmed John A. Stauffer Jordan D. LeGout Justin Burns Kristopher Croome Ricardo Paz-Fumagalli Gregory Frey Beau Toskich 《Journal of gastrointestinal oncology.》2021,12(2):751
BackgroundNeoadjuvant yttrium-90 transarterial radioembolization (TARE) is increasingly being used as a strategy to facilitate resection of otherwise unresectable tumors due to its ability to generate both tumor response and remnant liver hypertrophy. Perioperative outcomes after the use of neoadjuvant lobar TARE remain underinvestigated.MethodsA single center retrospective review of patients who underwent lobar TARE prior to major hepatectomy for primary or metastatic liver cancer between 2007 and 2018 was conducted. Baseline demographics, radioembolization parameters, pre- and post-radioembolization volumetrics, intra-operative surgical data, adverse events, and post-operative outcomes were analyzed.ResultsTwenty-six patients underwent major hepatectomy after neoadjuvant lobar TARE. The mean age was 58.3 years (17–88 years). 62% of patients (n=16) had primary liver malignancies while the remainder had metastatic disease. Liver resection included right hepatectomy or trisegmentectomy, left or extended left hepatectomy, and sectorectomy/segmentectomy in 77% (n=20), 8% (n=2), and 15% (n=4) of patients, respectively. The mean length of stay was 8.3 days (range, 3–33 days) and there were no grade IV morbidities or 90-day mortalities. The incidence of post hepatectomy liver failure (PHLF) was 3.8% (n=1). The median time to progression after resection was 4.5 months (range, 3.3–10 months). Twenty-three percent (n=6) of patients had no recurrence. The median survival was 28.9 months (range, 16.9–46.8 months) from major hepatectomy and 37.6 months (range, 25.2–53.1 months) from TARE.ConclusionsMajor hepatectomy after neoadjuvant lobar radioembolization is safe with a low incidence of PHLF. 相似文献